The IMDC (International Metastatic RCC Database Consortium) Risk Score for RCC predicts survival patients in metastatic renal cell carcinoma treated with systemic therapy.

Official website of the International mRCC Database Consortium (IMDC), including an up-to-date IMDC Prognosis Risk Calculator (IMDC Criteria / Heng Criteria) in addition to all past and present research fellows, publications, presentations and participating global institutions.

About IMDC Risk Categories: 75 – 80% of patients selecting 1st line mRCC treatment options have at least 1 of these risk factors, therefore classifying their mRCC as intermediate/poor risk. Risk classification may change over time and may help in selecting treatments such as immunotherapy. Legend: KPS = Karnofsky Performance Score

Consensus Statement: Choice of initial systemic treatment is based in part on International Metastatic RCC Database Consortium (IMDC) risk status. Consensus Statement: For IMDC favourable-risk patients, pembrolizumab + axitinib is the recommended treatment.

The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk criteria are currently the gold standard for predicting survival in patients with renal cell cancer (RCC) 5, 6. This method includes six risk factors: time from RCC diagnosis to first‐line systemic therapy <1 year, elevated platelet count, elevated absolute ...

The IMDC model characterizes patients as having favorable (no criteria), intermediate (one or two criteria), or poor (three or more criteria) risk. The IMDC model provides essential information to guide treatment decisions and predict the effectiveness of systemic therapy.

国际 mrcc 数据库联盟 (imdc) 为转移性 rcc (mrcc) 患者推荐了一种新的预后模型。在本研究中，我们旨在从外部验证 mrcc 患者 imdc 有利风险组的新型风险模型。 方法. 土耳其肿瘤组肾癌联合会 (tkcc) 是一个多中心登记处，包括土耳其的 13 个癌症中心。

IMDC Risk Model for Metastatic Renal Cell Carcinoma Predicts survival in patients with metastatic renal cell carcinoma treated with systemic therapy (also known as Heng criteria). <1 year from time of diagnosis to systemic therapy

2021年3月2日 · Conclusions: We identified a very favorable risk group in the IMDC criteria in RCC patients treated with first-line therapy. External validation including populations receiving IO containing therapies is ongoing.

The International Metastatic Renal-Cell Carcinoma Database Consortium’s (IMDC) prognostic model to predict survival of metastatic kidney cancer patients has become the standard model used in clinical trials to categorize patients into favorable, intermediate, and poor risk.